Start-Up Spotlight: Aria CV Addresses Right-Heart Failure With Purely Mechanical Solution
Executive Summary
St. Paul-based Aria CV is developing a "passive" pulmonary artery balloon system to treat pulmonary hypertension and impede the development of heart failure. Following a successful first-in-human study, the company is currently developing a feasibility study it expects will lead to a US pivotal trial in several years.
You may also be interested in...
QUOTED. Dec. 4, 2018. John Scandurra.
Aria CV hopes to address pulmonary hypertension, a potential devastating condition that currently has few treatments, with a unique balloon device that requires no power supply, battery, pump, or synchronization. See what Aria CEO John Scandurra said about it here.
New MDIC CEO Talks NEST, Case For Quality, CMS, And More
Two months into the job, Medical Device Innovation Consortium CEO Pamela Goldberg talks about the organization's work running the NEST Coordinating Center, its efforts to engage the Medicare agency, early feasibility studies and its work with US FDA on Case for Quality.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.